CV Therapeutics
Executive Summary
Cardiovascular drug discovery firm completes $16.6 mil. mezzanine round of financing through private placement of preferred stock. The Mountain View, Calif.-based company initiated its first clinical trial in February for CVT-1, an orally active cholesterol-lowering product designed to inhibit a "cholesterol transport protein that plays a key role in promoting the absorption of cholesterol from the intestine," the firm said. CVT was founded in 1992 and previously raised $13 mil. in two rounds of venture financing